PNC-27 CAS: 1159861-00-3 99% Purity Ss31 Oxytocin Acetate Dsip Pinealon Cortagen Foxo4-Drinad Ghk-Cu HMG Prostamax Pnc-27 PE-22-28 Dihexa Testagen Vi
TDS 3 Inquiries
1159861-00-3
Pharmaceutical Grade
99%
guangzhou
LM
5mg/vial 10vials/box
2027-01-26
Peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferencePNC-27 is an anti-cancer peptide that, in small in-vitro studies, has been shown to induce tumour cell necrosis. It is not currently approved for use in the United States (U.S.) and is currently being marketed online as a non-toxic potential cure for various cancers. Recently, the FDA issued warnings to the public regarding PNC-27 use, suggesting possible contamination and unknown side effects of the treatment. PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository. FDA has not evaluated or approved PNC-27 as safe and effective in treating any disease, including cancer[1].
PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research.CertificatesBasic Info-
Product Name:
PNC-27
Other Name:PNC27
CAS No.:1159861-00-3
Molecular Weight:0
Categories:
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptides
-
Location:
Jinxing Middle Road, Xihu Street, Yuelu District, Changsha City, Hunan Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
Certifications:
COA
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted 
United States
PNC27
10 PCS Apr 11, 2026
United States
PNC-27
1 PCS Sep 4, 2026
United States
PNC-27
5 MG Sep 4, 2026 Post an enquiry for this product
